青蒿素之后，又一款从源头创新的救命药在中国诞生

Core Viewpoint - The article highlights the significant achievement of Huahui Anjian, a Chinese pharmaceutical company, in developing its first fully innovative drug, Libeweita, which marks a milestone in China's pharmaceutical history and represents a shift towards original innovation in the industry [4][13]. Group 1: Company Background and Development - Huahui Anjian was founded in 2015 by researchers from the Beijing Institute of Life Sciences, including Li Wenhui and Sui Jianhua, amidst a supportive environment for drug review reforms initiated by the Chinese government [4][6]. - The company has grown from a small startup with a few employees to a prominent player with over a hundred staff and multiple clinical-stage pipelines [4][6]. - The approval of Libeweita, a monoclonal antibody drug for chronic hepatitis D, is a result of over a decade of research and development, beginning with Li Wenhui's discovery of the hepatitis B virus receptor in 2012 [6][8]. Group 2: Drug Development Process - The development of Libeweita involved extensive clinical trials, starting with Phase I trials in 2019, which demonstrated good safety profiles [8][9]. - The drug received "breakthrough therapy" designation from the National Medical Products Administration of China in April 2023, indicating its potential to address unmet medical needs [10][13]. - Libeweita was officially approved for market release on January 23, 2026, after a rigorous clinical trial process that showcased its efficacy in blocking the infection process of hepatitis viruses [13][18]. Group 3: Market Potential and Future Plans - There are approximately 12 million global hepatitis D virus infections, with China potentially having over 600,000 cases, indicating a significant market need for effective treatments [18][21]. - Following the drug's launch, Huahui Anjian aims to expand its international presence, particularly in countries along the "Belt and Road" initiative where hepatitis D is prevalent [19][20]. - The company plans to offer Libeweita at different price points in various markets, ensuring accessibility while maintaining a global pricing strategy [20][21]. Group 4: Company Culture and Challenges - Huahui Anjian fosters a culture of equality and open communication, which is rooted in its origins at the Beijing Institute of Life Sciences [24][25]. - The company faced significant challenges during the COVID-19 pandemic and subsequent market downturn, leading to staff reductions and financial strain [28][29]. - Despite these challenges, the company secured crucial funding in March 2024, allowing it to continue its operations and prepare for the launch of Libeweita [28][29].